title: An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease.
abstract: A prospective, randomized study compared the effects of equivalent intravenous doses of three slow calcium-channel blockers (verapamil, diltiazem, and amlodipine) on rest and exercise haemodynamics in 30 ischemic heart disease patients. Following a stable control period during which rest and exercise (supine bicycle) hemodynamics were assessed, equivalent hypotensive doses of each compound were administered over 20 minutes and rest/exercise parameters were assessed 10 minutes later. At rest all agents similarly reduced systemic blood pressure; the fall in systemic vascular resistance and the increase in cardiac indices was ranked: amlodipine greater than diltiazem greater than verapamil. The heart rate increase for amlodopine differed from verapamil and diltiazem (+19.4% vs. +1.5% vs. -7%; p less than 0.01). On exercise, similarly greater falls in the systemic vascular resistance index followed amlodipine, compared with verapamil and diltiazem (p less than 0.05). Only amlodipine significantly reduced the exercise pulmonary artery occlusion pressure (PAOP). Exercise cardiac stroke volume improved after diltiazem and amlodipine. In terms of cardiac performance, both amlodipine and diltiazem produced an improvement, whereas verapamil depressed cardiac pumping activity. Thus, hemodynamic differences between slow-calcium-channel blocking drugs may be demonstrated in humans. These differences would be compatible with a predominant peripheral vascular site of action for amlodipine, in contrast with mixed cardiac and peripheral sites for diltiazem and verapamil.
authors: University Department of Cardiovascular Studies, General Infirmary at Leeds, UK.
authors: B
authors: B
authors: Silke
authors: E
authors: E
authors: Goldhammer
authors: S K
authors: SK
authors: Sharma
authors: S P
authors: SP
authors: Verma
authors: S H
authors: SH
authors: Taylor
mesh_terms: D017311:Amlodipine; D000787:Angina Pectoris / Q000188:drug therapy / Q000209:etiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002302:Cardiac Output / Q000187:drug effects; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D004110:Diltiazem / Q000627:therapeutic use; D015444:Exercise / Q000502:physiology*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D009543:Nifedipine / Q000031:analogs & derivatives / Q000627:therapeutic use; D011446:Prospective Studies; D012146:Rest / Q000502:physiology; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D017311:Amlodipine; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine